| Weight | 1 lbs |
|---|---|
| Dimensions | 9 × 5 × 2 in |
| target | Influenza B Virus reactive IgG |
| species reactivity | Influenza B Virus |
| applications | ELISA |
| assay type | Indirect & quantitative |
| available size | 3 mL |
Influenza B Virus IgG Control Serum BC1232G
$94.00
Summary
- Virion/Serion Diagnostic Kit Control for research use (RUO)
- Influenza
- Applications: ELISA
- IgG control serum
- Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
- 3 mL
Influenza B Virus IgG Control Serum BC1232G
| kit |
|---|
| Research area Infectious Disease |
| Storage Store at 2-8°C. |
| Associated products Influenza B Virus IgA Control Serum (BC1232A) Influenza B Virus IgG Control Serum (BC1232G) Influenza B Virus IgM Control Serum (BC1232M) Influenza B Virus IgA ELISA Kit (ESR1232A) Influenza B Virus IgG ELISA Kit (ESR1232G) Influenza B Virus IgM ELISA Kit (ESR1232M) |
| target relevance |
|---|
| Aspergillus fumigatus |
| Description Fungus that causes aspergillosis and invasive fungal infections |
| Structure Aspergillus fumigatus is a filamentous fungus belonging to the family Aspergillaceae and is the most common cause of human aspergillosis. The organism is widely distributed in the environment and is commonly found in soil, compost, decaying vegetation, stored grain, and airborne organic matter. Aspergillus fumigatus reproduces through the formation of abundant airborne asexual spores known as conidia, which are readily inhaled by humans on a daily basis. The fungus exhibits thermotolerance and can grow at temperatures exceeding those of many other environmental fungi, contributing to its pathogenic potential. In healthy individuals, inhaled conidia are efficiently cleared by innate immune defenses; however, in immunocompromised hosts or individuals with underlying lung disease, the fungus may germinate and invade tissues. Aspergillus fumigatus is capable of forming hyphae that penetrate host tissues and blood vessels, resulting in significant tissue damage and dissemination. |
| Diagnosis The diagnosis of Aspergillus fumigatus infection is performed through microbiological, histopathological, serological, molecular, and radiological methods. Culture of respiratory specimens, bronchoalveolar lavage fluid, or tissue samples may yield Aspergillus species, although culture alone does not always distinguish colonization from invasive disease. Microscopic examination may reveal characteristic septate hyphae with acute-angle branching. Detection of galactomannan antigen and beta-D-glucan in blood or respiratory samples is commonly used to support the diagnosis of invasive aspergillosis. Polymerase chain reaction (PCR) assays provide sensitive detection of Aspergillus DNA and are increasingly used in specialized laboratories. Imaging studies, particularly computed tomography (CT) of the chest, often demonstrate characteristic pulmonary findings such as nodules, cavitary lesions, or the halo sign. Definitive diagnosis may require histopathological evidence of tissue invasion. |
| Symptoms Clinical manifestations of Aspergillus fumigatus infection vary according to the host's immune status and underlying lung disease. Allergic bronchopulmonary aspergillosis (ABPA) commonly presents with wheezing, cough, mucus production, and worsening asthma symptoms. Chronic pulmonary aspergillosis may cause persistent cough, fatigue, weight loss, shortness of breath, and hemoptysis. Invasive aspergillosis, which primarily affects severely immunocompromised individuals, often presents with fever, chest pain, cough, shortness of breath, and progressive pulmonary infiltrates despite antibacterial therapy. The infection may disseminate to the brain, kidneys, heart, liver, and other organs, resulting in neurological symptoms, organ dysfunction, and sepsis. Without prompt diagnosis and antifungal treatment, invasive aspergillosis is associated with high morbidity and mortality. |
Data
FAQ & Publications
Frequently Asked Questions
What is the intended application for the Influenza B Virus IgG Control Serum BC1232G?
The Influenza B Virus IgG Control Serum BC1232G is designed for use as a control serum in ELISA assays, specifically for indirect and quantitative detection of Influenza B Virus reactive IgG antibodies.
How should the Influenza B Virus IgG Control Serum BC1232G be stored to maintain its stability?
The Influenza B Virus IgG Control Serum BC1232G should be stored refrigerated at 2-8°C to ensure product stability and optimal performance.
Is the Influenza B Virus IgG Control Serum BC1232G compatible with specific ELISA kits?
Yes, this control serum is ready-to-use and pre-diluted for compatibility with SERION ELISA classic and SERION ELISA antigen assays.
Publications
| pmid | title | authors | citation |
|---|---|---|---|
| We haven't added any publications to our database yet. | |||
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from the PubMed database provided by the United States National Library of Medicine at the National Institutes of Health.
Protocols
| relevant to this product |
|---|
| BC1232G protocol |
Only logged in customers who have purchased this product may leave a review.
Reviews
There are no reviews yet.